Inhibition of rheumatoid arthritis by blocking connective tissue growth factor  

作　　者：Kazuhisa Nozawa Maki Fujishiro Yoshinari Takasaki Iwao Sekigawa 

机构地区：[1]Department of Rheumatology, School of Medicine, Juntendo University [2]Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine [3]Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital

出　　处：《World Journal of Orthopedics》2014年第5期653-659,共7页世界骨科杂志（英文版）

基　　金：Supported by Grant-in-Aid for Scientific Research(C),The Ministry of Education,Culuture,Sports,Science and Technology and The Institute for Environment and Gender-specific Medicine,Juntendo University Graduate School of Medicine

摘　　要：The pathogenesis of rheumatoid arthritis(RA) remains to be completely elucidated so far; however, it is known that proinflammatory cytokines play a pivotal role in the induction of RA. Tumor necrosis factor(TNF-α), in particular, is considered to play a central role in bone destruction by mediating the abnormal activation of osteoclasts or the production of proteolytic enzymes through direct or indirect mechanisms. The use of TNF-α blocking agents has a significant impact on RA therapy. Anti-TNF-α blocking agents such as infliximab are very effective for treatment of RA, especially for the prevention of articular destruction. We have previously shown that several proteins exhibited extensive changes in their expression after amelioration of RA with infliximab treatment. Among the proteins, connective tissue growth factor(CTGF) has a significantrole for the development of RA. Herein, we review the function of CTGF in the pathogenesis of RA and discuss the possibility of a novel treatment for RA. We propose that CTGF is a potentially novel effector molecule in the pathogenesis of RA. Blocking the CTGF pathways by biological agents may have great beneficial effect in patients with RA.The pathogenesis of rheumatoid arthritis(RA) remains to be completely elucidated so far; however, it is known that proinflammatory cytokines play a pivotal role in the induction of RA. Tumor necrosis factor(TNF-α), in particular, is considered to play a central role in bone destruction by mediating the abnormal activation of osteoclasts or the production of proteolytic enzymes through direct or indirect mechanisms. The use of TNF-α blocking agents has a significant impact on RA therapy. Anti-TNF-α blocking agents such as infliximab are very effective for treatment of RA, especially for the prevention of articular destruction. We have previously shown that several proteins exhibited extensive changes in their expression after amelioration of RA with infliximab treatment. Among the proteins, connective tissue growth factor(CTGF) has a significantrole for the development of RA. Herein, we review the function of CTGF in the pathogenesis of RA and discuss the possibility of a novel treatment for RA. We propose that CTGF is a potentially novel effector molecule in the pathogenesis of RA. Blocking the CTGF pathways by biological agents may have great beneficial effect in patients with RA.

关 键 词：CONNECTIVE tissue growth facto RHEUMATOID ARTHRITIS OSTEOCLASTS Condrocytes Tumor NECROSIS factor-α 

分 类 号：R593.22[医药卫生—内科学]